Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Douglas E. Love
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 92
- Beta
- 1.22
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -1.08
Financials
Net Income
$-55.35MEBITDA
$-54.81MFree Cash Flow
$-48.14MEPS (diluted)
$-0.28Shares Outstanding (diluted)
201.00M+53837.6%Operating Expenses
$57.23MCash & Debt
$209.24MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-206.69M | $-1.34 |
| 2024 | $0.00 | $-138.20M | $-1.01 |
| 2023 | $0.00 | $-134.24M | $-1.77 |
| 2022 | $0.00 | $-141.95M | $-2.60 |
| 2021 | $0.00 | $-130.32M | $-3.34 |
| 2020 | $0.00 | $-63.41M | $-3.70 |
| 2019 | $0.00 | $-37.18M | $-0.97 |
| 2018 | $0.00 | $-18.30M | $-1.60 |
| 2017 | $0.00 | $-18.71M | $-0.49 |
Valuation
ANNXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-67.48%Social Signal Score
Mentions (9)
- Newsseekingalpha.com·9d ago·Neutral
…ets functional patient outcomes in geographic atrophy and Guillain-Barré syndrome, aiming for clinical differentiation via vision and physical recovery preservation. ANNX maintains a cash runway into 2028, supported by $209.2M in liquidity and a $200M Oxford Finance facility, but future financing remains a risk. The ARCHER II trial pivots to functional vision endpoints, with key readouts expected in Q4 2026 and potential market expansion if vision preservation is confirmed.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
…ision in Geographic Atrophy, with Month 15 Results Expected in the Fourth Quarter of 2026 BRISBANE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced two oral presentations on vonaprument at The Retina Society 59th Annual Scientific Meeting being held September 23-26, 2026 in Los A…
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The eq…
View source ↗ - Newsglobenewswire.com·34d ago·Positive
Annexon to Participate in Upcoming September Investor Conferences BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:
View source ↗ - Newsglobenewswire.com·49d ago·Neutral
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The e…
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·55d ago·Positive
Annexon Q2 Earnings Call Highlights Annexon NASDAQ: ANNX said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study's existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the 15-month endpoint while seeking to capture longer-term efficacy data for a potential product label.
View source ↗ - Newsglobenewswire.com·55d ago·Negative
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a Month
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.28 per share
Typical surprise -8.8% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.28 vs $-0.24miss
- Thu, May 7$-0.23 vs $-0.30beat
- Mon, Mar 30$-0.28 vs $-0.32beat
- Mon, Nov 10$-0.37 vs $-0.34miss
- Thu, Aug 14$-0.34 vs $-0.36beat
- Mon, May 12$-0.37 vs $-0.30miss
Estimates and results for ANNX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ANNX officers and directors.
- Bought
- $12.5m
- Sold
- $636k
22 trades
30 trades
- Love Douglasbought
- Satter Muneer Abought
- Carson William H.bought
- Carson William H.bought
- Carson William H.bought
- Dananberg Jamiesold
- Overdorf Michaelsold
- Yednock Tedsold
48 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ANNX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.